World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing

AIDS

Volumn 15, Issue 13, 2001, Pages 1671-1677

  Harrigan, P Richard ^a,b,c,g   Montaner, Julio S G ^b,c   Wegner, Scott A ^d   Verbiest, Werner ^a   Miller, Veronica ^e   Wood, Robin ^f   Larder, Brendan A ^a  

^a Virco UK Ltd   (United Kingdom)

^b ST PAUL S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d US Military HIV Research Program   (United States)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Antivirogram; Distribution; Drug resistance; HIV; Phenotypic resistance tests; Phenotypic susceptibility; World wide

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG SENSITIVITY; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS RECOMBINANT; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; WORLD HEALTH;

EID: 0035822981     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200109070-00010     Document Type: Article

References (32)

1. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
2. Clinical Laboratory Guidelines for use of HIV-1 drug resistance testing as part of treatment management
3. Clinical utility of testing human immunodeficiency virus for drug resistance
4. Transmission of antiretroviral-drug-resistant HIV-1 variants
5. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel
6. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study
7. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
8. HIV-1 drug resistance in newly infected individuals
9. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
10. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy
11. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy naive patients (study DMP 266-006)
12. The World Health Organization Global Programme on AIDS proposal for standardization of HIV sequence nomenclature. WHO network for HIV isolation and characterization
13. Pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D
14. Prevalence of phenotypic and genotypic resistance in recently infected, antiretroviral inexperienced patients: The German HIV-research initiative cohort
15. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
16. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
17. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro
18. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing
19. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: The virtual phenotype
20. Testing for HIV-1 drug resistance: New developments and clinical implications
21. Resistance to HIV protease inhibitors
22. Phenotypic testing predicts virological response in successive protease inhibitor-based regimens
23. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain
24. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users
25. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: Outcome after treatment in recently infected individuals
26. Transmission and prevalence of HIV resistance among treatment-naive subjects
27. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion
28. The application of neural networks in predicting phenotypic resistance from genotypes for HIV-1 protease inhibitors
29. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184
30. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy